The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Therapeutic Pipeline Program, 2019Mapping Brain Response Patterns to Deep Brain Stimulation with FMRI
Study Rationale:
Deep brain stimulation (DBS) targets malfunctioning brain circuits. Commonly used to treat Parkinson’s disease (PD), this surgical therapy can produce striking clinical benefits when... -
Epidemiological Parkinson's Risk Modifiers, 2019Study in Norwegian Population to Identify Therapies with Repurposing Potential for Parkinson’s Disease
Study Rationale:
There are not yet medicines that can prevent or slow Parkinson’s disease. Developing a new therapeutic can cost up to 2.6 billion dollars and takes many years of screening, chemistry... -
Therapeutic Pipeline Program, 2019Managing Levodopa-induced Dyskinesias by Targeting Dopamine D1 Receptor Signaling
Study Rationale:
Parkinson’s is a complex brain disease caused by the gradual loss of brain cells producing the neurotransmitter dopamine, which controls movement, emotion and affect. However... -
Access to Data and Biospecimens, 2019Convergence of LRRK2 and GBA in the Pathogenesis of Parkinson’s Disease Supplement
Promising Outcomes of Original Grant:
In our original project we used dopamine cells derived from induced pluripotent stem cells (iPSCs) from people with Parkinson’s-associated LRRK2 or GBA mutations... -
Therapeutic Pipeline Program, 2019Small Molecule Therapeutics Targeting Nurr1
Study Rationale:
Nurr1 is a protein that plays critical roles in the development, maintenance and survival of dopaminergic neurons and, as such, is a potential therapeutic target for treating the... -
Target Advancement Program, 2019Investigating Vulnerability of Subsets of Dopaminergic Neurons
Study Rationale:
Brain cells that produce the neurotransmitter dopamine are the most vulnerable to cell death in Parkinson’s disease (PD), but the reasons for this are not known. New techniques have...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.